ABO 2011
Alternative Names: ABO-2011; ABOD-2011Latest Information Update: 19 Jul 2024
At a glance
- Originator Suzhou Abogen Biosciences
- Class Antineoplastics; Immunotherapies; Interleukins; RNA
- Mechanism of Action Interleukin 12 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Jul 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (Intratumoural) (NCT06088004)